Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | CCR3 | P51677 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153469 | 0.84 | GAA (0.80) | GAADRD2MEN1KMT2ACCR3 | |
| SCHEMBL6154675 | 0.84 | HTR2A (0.60) | DRD2DRD4KMT2ALMNA | |
| SCHEMBL6153849 | 0.82 | GAA (1.00) | GAAMEN1KMT2ACCR3ALDH1A1 | |
| SCHEMBL14689861 | 0.81 | NPC1 (0.61) | DRD2DRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL8549859 | 0.81 | DRD2 (0.85) | DRD2DRD4 | |
| SCHEMBL12642472 | 0.80 | CCR3 (0.81) | GAACCR3ALDH1A1 | |
| SCHEMBL2004615 | 0.80 | CCR3 (1.00) | GAAMEN1KMT2ACCR3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8555532 | 0.80 | DRD2 (0.83) | DRD2DRD4 | |
| SCHEMBL14601873 | 0.79 | DRD2 (0.66) | DRD2DRD4 | |
| SCHEMBL7977320 | 0.78 | CCR3 (0.96) | GAAMEN1KMT2ACCR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | GAA 2875/4885DRD2 3058/4885DRD4 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.